Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inosine + methionine + nicotinamide + succinic acid
- Development stage
- Unknown
- Lead developer
- POLYSAN
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Remaxa is a hepatoprotective and antioxidant combination drug developed by Polysan Ltd. It consists of four active components: inosine, methionine, nicotinamide, and succinic acid. The drug is primarily indicated for the treatment of chronic diffuse liver diseases, including viral hepatitis, toxic (drug-induced) liver injury, and non-alcoholic fatty liver disease, particularly when complicated by intrahepatic cholestasis. Remaxa acts as a stimulant for Beta-nerve growth factor (NGFB) and metabolic processes, helping to reduce cytolysis and improve liver function. It was developed as an oral, enteric-coated tablet formulation to provide a solid-form alternative to the infusion solution Remaxol (which contains the same active metabolites plus meglumine).
- Brand names
- Remaxa
- Other names
- Succinate/Methionine/Inosine/Nicotinamide
02
Targets
SDH (Mitochondrial electron transport chain complex II)PNP (Purine nucleoside phosphorylase)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on inosine + methionine + nicotinamide + succinic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inosine + methionine + nicotinamide + succinic acid.